General Information of Drug (ID: DM0CL4I)

Drug Name
MCS-110 Drug Info
Synonyms Colony stimulating factor-1 inhibiting antibody (cancer), Novartis; Anti-CSF-1 antibody (cancer), Novartis
Indication
Disease Entry ICD 11 Status REF
Bone metastases 2D50 Phase 2 [1]
Tenosynovial giant cell tumour 2F7B Phase 2 [2]
Triple negative breast cancer 2C60-2C65 Phase 2 [2]
Advanced malignancy 2A00-2F9Z Phase 1/2 [2]
Breast cancer 2C60-2C65 Phase 1 [3]
Cross-matching ID
TTD Drug ID
DM0CL4I

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ARRY-382 DM0VGDC Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
RG7155 DM8JMNL Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
JNJ-40346527 DM219SF Hodgkin lymphoma 2B30 Phase 2 [7]
PD-360324 DM6F5EV Rheumatoid arthritis FA20 Phase 2 [8]
FPA-008 DM3ZN6Y Autoimmune diabetes 5A10 Phase 1/2 [9]
AMG 820 DMB6Q19 Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
IMC-CS4 DMUYN26 Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Colony stimulating factor-1 receptor (CSF-1R) TT731LW E9PEK4_HUMAN Modulator [4]

References

1 ClinicalTrials.gov (NCT01643850) MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5 Company report (Array)
6 Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014 Jun 16;25(6):846-59.
7 An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clin Cancer Res. 2015 Apr 15;21(8):1843-50.
8 Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus.Clin Exp Immunol.2016 Feb;183(2):258-70.
9 Company report (Five Prime Therapeutics)